New drug combo shows promise against tough skin cancer
NCT ID NCT06288191
First seen Jan 04, 2026 · Last updated May 11, 2026 · Updated 13 times
Summary
This study tests whether giving two immunotherapy drugs (nivolumab and relatlimab) before surgery can shrink advanced skin cancer (cutaneous squamous cell carcinoma) and lower the chance of it coming back. About 20 adults with stage II to IV cancer that can be surgically removed will receive the drugs for 6 weeks, then have surgery. The main goal is to see how many patients have no cancer cells left in the removed tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Melanoma Institute Australia
RECRUITINGWollstonecraft, New South Wales, 2065, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.